Use of aldosterone antagonists at discharge after myocardial infarction: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG)

American Heart Journal

Volumn 166, Issue 4, 2013, Pages 709-715

  Rao, Krishnasree K ^a   Enriquez, Jonathan R ^b   De Lemos, James A ^a   Alexander, Karen P ^c   Chen, Anita Y ^c   McGuire, Darren K ^a   Fonarow, Gregg C ^d   Das, Sandeep R ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE RECEPTOR INHIBITOR; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE REGISTRY; DRUG USE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL DISCHARGE; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; UNITED STATES;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84885181092     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.06.020     Document Type: Article

References (26)

1. B. Pitt, W. Remme, and F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
2. E.M. Antman, M. Hand, and P.W. Armstrong 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 117 2008 296 329
3. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 50 2008 e1 e157
4. A.N. Rassi, M.A. Cavender, and G.C. Fonarow Temporal trends in the use of aldosterone antagonists post-acute myocardial infarction J Am Coll Cardiol 61 2013 35 40
5. M.T. Roe, J.C. Messenger, and W.S. Weintraub Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention J Am Coll Cardiol 56 2010 254 263
6. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
7. F. Zannad, J.J. McMurray, and H. Krum Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
8. N.M. Albert, C.W. Yancy, and L. Liang Use of aldosterone antagonists in heart failure JAMA 302 2009 1658 1665
9. M. Gheorghiade, N.M. Albert, and A.B. Curtis Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF Congest Heart Fail 18 2012 9 17
10. E. López-de-Sá, A. Martínez, and M. Anguita Aldosterone receptor antagonist use after myocardial infarction. Data from the REICIAM registry Rev Esp Cardiol 64 2011 981 987
11. E.H. Bradley, J. Herrin, and J.A. Mattera Quality improvement efforts and hospital performance: rates of beta-blocker prescription after acute myocardial infarction Med Care 43 2005 282 292
12. W.J. Rogers, J.G. Canto, and C.T. Lambrew Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3 J Am Coll Cardiol 36 2000 2056 2063
13. G.C. Fonarow, W.J. French, and P.D. Frederick Trends in the use of lipid-lowering medications at discharge in patients with acute myocardial infarction: 1998 to 2006 Am Heart J 157 2009 185 194
14. S.A. Hunt, W.T. Abraham, and M.H. Chin 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 e391 e479
15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
16. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators N Engl J Med 325 1991 293 302
17. M. Packer, A.J. Coats, and M.B. Fowler Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658
18. C.B. Granger, J.J. McMurray, and S. Yusuf Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
19. D.N. Juurlink, M.M. Mamdani, and D.S. Lee Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 2004 543 551
20. B. Bozkurt, I. Agoston, and A.A. Knowlton Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines J Am Coll Cardiol 41 2003 211 214
21. K.B. Shah, K. Rao, and R. Sawyer The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure J Am Coll Cardiol 46 2005 845 849
22. B. Scherstén, T. Thulin, and J. Kuylenstierna Clinical and biochemical effects of spironolactone administered once daily in primary hypertension. Multicenter Sweden study Hypertension 2 1980 672 679
23. M. de Gasparo, U. Joss, and H.P. Ramjoué Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro J Pharmacol Exp Ther 240 1987 650 656
24. J.H. O'Keefe, H. Abuissa, and B. Pitt Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS Diabetes Obes Metab 10 2008 492 497
25. P. Bogaty, S. Dumont, and G.E. O'Hara Randomized trial of a noninvasive strategy to reduce hospital stay for patients with low-risk myocardial infarction J Am Coll Cardiol 37 2001 1289 1296
26. C. Adamopoulos, A. Ahmed, and R. Fay Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial Eur J Heart Fail 11 2009 1099 1105